267 related articles for article (PubMed ID: 38087976)
1. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Mansur RB; Rosenblat JD; Kwan ATH
Expert Opin Drug Saf; 2024 Jan; 23(1):47-55. PubMed ID: 38087976
[TBL] [Abstract][Full Text] [Related]
2. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
Guirguis A; Chiappini S; Papanti P GD; Vickers-Smith R; Harris D; Corkery JM; Arillotta D; Floresta G; Martinotti G; Schifano F
Eur Neuropsychopharmacol; 2024 May; 82():82-91. PubMed ID: 38508100
[TBL] [Abstract][Full Text] [Related]
3. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
4. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
Tobaiqy M; Elkout H
Int J Clin Pharm; 2024 Apr; 46(2):488-495. PubMed ID: 38265519
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
Ruggiero R; Mascolo A; Spezzaferri A; Carpentieri C; Torella D; Sportiello L; Rossi F; Paolisso G; Capuano A
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399362
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
8. Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS; Aroda VR; Parlett LE; Djebarri L; Berreghis S; Calingaert B; Beachler DC; Crowe CL; Johannes CB; Juhaeri J; Lanes S; Pan C; Rothman KJ; Saltus CW; Walsh KE
Diabetes Care; 2024 Apr; 47(4):712-719. PubMed ID: 38363873
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas.
McIntyre RS
Expert Opin Drug Saf; 2024 May; 23(5):539-542. PubMed ID: 38520274
[No Abstract] [Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Zhou J; Zheng Y; Xu B; Long S; Zhu LE; Liu Y; Li C; Zhang Y; Liu M; Wu X
BMC Med; 2024 Feb; 22(1):65. PubMed ID: 38355513
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
15. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
Cao M; Pan C; Tian Y; Wang L; Zhao Z; Zhu B
Int J Clin Pharm; 2023 Jun; 45(3):689-697. PubMed ID: 36977858
[TBL] [Abstract][Full Text] [Related]
17. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.
Chen C; Zhou R; Fu F; Xiao J
Eur Psychiatry; 2023 Nov; 66(1):e99. PubMed ID: 38031404
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
[TBL] [Abstract][Full Text] [Related]
19. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
20. GLP-1 receptor agonists: A review of glycemic benefits and beyond.
Clark L
JAAPA; 2024 Apr; 37(4):1-4. PubMed ID: 38531038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
